February 9, 2012

Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences

CAMBRIDGE, Mass., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that the company will participate in the 14th Annual BIO CEO & Investor Conference in New York City. Marc Beer, Chief Executive Officer of Aegerion, is scheduled to present on Tuesday, February 14, 2012 at 9:30 a.m. ET.

Aegerion will also participate in the Leerink Swann 2012 Global Healthcare Conference in New York City. Mr. Beer is scheduled to present on Thursday, February 16, 2012 at 8:00 a.m. ET.

The presentations will be webcast live and may be accessed for 90 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia.

CONTACT: Aegerion Pharmaceuticals, Inc.

         Corporate

         Mark Fitzpatrick, CFO

         +1 (617) 500-6235

         

         LaVoie Group, Inc.

         Investors & Media

         Amanda Murphy

         +1 (978) 745-4200 x107

         amurphy@lavoiegroup.com


Close window | Back to top

Copyright 2014 Aegerion Pharmaceuticals, Inc.